Biocartis has entered into a research collaboration with Mayo Clinic to develop a rapid sample-to-answer test for breast cancer. The test aims to shorten the time to optimal treatment by providing faster access to diagnostic results.
Under the collaboration, Mayo Clinic will provide clinical expertise, archived samples, and pathology services to accelerate assay development, validation, and market access. The test is investigational and not yet available for diagnostic use.
“Optimal care depends on timely access to test results. Rapid local diagnostics can shorten the time to determine patients’ appropriate therapeutic pathway. Our goal is to help make faster testing available to breast cancer patients,” said Matthew P. Goetz, MD, medical oncologist at Mayo Clinic.
Roger Moody, CEO of Biocartis, said: “We are excited to collaborate with Mayo Clinic as we seek to bring rapid, high-value testing to breast cancer patients. Our goal is to use this as a first step toward expanding into larger markets including gene signatures, patient monitoring, and early detection.”
Biocartis develops the Idylla platform, which delivers in-house molecular biomarker results in approximately three hours. The company’s diagnostic portfolio spans multiple cancers including lung, skin, thyroid, colorectal, and breast cancer.
